A large open multicentre trial of clomipramine (Anafranil) in the management of phobic disorders.
In a large, open, multicentre trial, conducted in general practice, 765 patients suffering from agoraphobia or social phobias were treated with clomipramine (Anafranil, Geigy Pharmaceuticals). Four hundred and eight patients completed a twelve-week course of treatment. Of 285 withdrawals, 139 were due to side-effects. Good results were obtained on all measures of phobias in those patients who completed the study, the improvements being of the order of 70-80%, and over 50% of patients being symptom-free.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000379:Agoraphobia / Q000188:drug therapy / Q000523:psychology; D002997:Clomipramine / Q000009:adverse effects / Q000627:therapeutic use*; D003984:Dibenzazepines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008393:Marriage; D008875:Middle Aged; D010352:Patient Dropouts; D010698:Phobic Disorders / Q000188:drug therapy* / Q000523:psychology
D003984:Dibenzazepines; D002997:Clomipramine